



Correction: Interim Report 220701-220930

Press Release 7 December, 2022

In November 2022, the company discovered a misstatement of grants in the Q3 report, as the government grants received are reported as other operating income. The terms of the government grants require the grants to fund the company's development projects and are recorded as advance government grants on the balance sheet. The net amount does not affect the cash flow of the enterprise but is a transfer from the income statement to the balance sheet.

The impact on the Parent Company and the Group for Q3, 2022 will be as follows:

Income Statement	Parent Company			Group		
	Q3	New Q3	Change	Q3	New Q3	Change
Other operating income	13 461 835	571 540	- 12 890 295	14 365 624	626 121	- 13 739 504
Other operating expenses	- 63 739	- 396 258	- 332 519	- 211 235	- 543 754	- 332 519
Profit/Loss After Financial Items	8 997 861	- 4 224 953	- 13 222 814	2 998 939	- 11 073 084	- 14 072 023
Earnings per share	0.09	0.33	0.42	0.09	0.33	0.42
Balance Sheet						
Intangible Fixed Assets	90 381 136	85 710 298	- 4 670 838	96 805 915	92 135 078	- 4 670 838
TOTAL ASSETS	121 112 466	116 441 628	- 4 670 838	122 003 532	117 332 695	- 4 670 838
Fund for development expenditures	81 474 453	85 710 298	4 235 845	81 474 453	92 135 078	10 660 625
Other equity incl. profit for the year	29 929 026	11 621 159	- 18 307 867	29 867 053	5 134 406	- 24 732 647
Total Equity	114 721 825	100 649 803	- 14 072 022	114 659 853	100 587 830	- 14 072 023
Advances from Grants	-	9 401 184	9 401 184	-	9 401 184	9 401 184
Total Short-term liabilities	4 682 567	14 083 751	9 401 184	5 635 606	15 036 790	9 401 184
TOTAL EQUITY AND LIABILITIES	121 112 466	116 441 628	- 4 670 838	122 003 532	117 332 695	- 4 670 838
Balance sheet total	121 112 466	116 441 628	- 4 670 838	122 003 532	117 332 695	- 4 670 838
Equity/assets ratio	95%	86%	-9%	94%	86%	-8%
Cash Flow Statements						
Cash Flow from Operating Activities	- 3 440 424	- 8 111 262	- 4 670 838	2 984 364	- 1 686 475	- 4 670 838
Cash Flow from Investing Activities	- 17 033 802	- 12 362 964	- 4 670 838	- 23 458 503	- 18 787 665	- 4 670 838
Cash Flow For the Period	- 20 595 230	- 20 595 230	-	- 20 595 143	- 20 595 143	-

For more information please contact:

Ina Laura Perkins, CEO

Phone: +46(0)70 406 49 21

E-mail: inalaura.perkins@realheart.se

Certified Adviser: Svensk Kapitalmarknadsgranskning AB, Phone: +46 11 32 30 732,
email: ca@skmg.se

Scandinavian Real Heart AB develops a total artificial heart (TAH) for implantation in patients with life-threatening heart failure. Realheart® TAH has a patented design that resembles that of the natural human heart. The artificial heart consists of a four-chamber system (two atria and two ventricles) designed to generate a physiological blood flow pattern that mimics the body's natural circulation. A unique concept in the medical technology world.